Funding for this research was provided by:
National Center for Advancing Translational Sciences (8UL1TR000090-05)
National Cancer Institute (5K12 CA133250-09, 2 P30 CA016058-42)
Pelotonia New Investigator (.)
Text and Data Mining valid from 2020-05-06
Received: 16 September 2019
Accepted: 21 April 2020
First Online: 6 May 2020
Consent for publication
: Not applicable.
: DHO has a consulting or advisory role to L&M Policy Research and AstraZeneca. DHO has research funding from Bristol-Myers Squibb, Palobiofarma, Merch Sharp & Dohme and Genentech/Roche. DHO received travel, accommodations and/or expenses from AstraZeneca. DPC is on the advisory board of Abbvie, AMGEN, Ariad, AZ, Biocept, BI, BMS, Celgene, EMD Serono, Genentech, Gritstone, Helsinn, Inivata, Inovio, Janssen, Loxo Oncology, Merck, MSD, Pfizer, Roche, Takeda, and Trinity. DPC received honoraria from AstraZeneca and Nexus Oncology. DPC is a consultant for Abbvie, Agenus, Ariad, Celgene, Genentech, Incyte, Inivata, Janssen, Kyowa Kirin, Loxo, MSD, Novartis, Pfizer and Takeda.